What is NuProbe?
NuProbe operates at the intersection of advanced genomics and molecular diagnostics, focusing on enhancing the sensitivity of sequencing mutations and copy number variations. With a global operational presence spanning Houston and key hubs in China, the company is dedicated to advancing precision medicine through high-fidelity diagnostic tools. Its core value proposition lies in its ability to improve detection sensitivity by over 10-fold, providing researchers with the granular data necessary to improve patient outcomes. While currently positioned for Research Use Only, the firm's technological advancements are pivotal for the future of clinical diagnostics and personalized healthcare.
How much funding has NuProbe raised?
NuProbe has raised a total of $58.3M across 3 funding rounds:
Series A
$11M
Unspecified
$42M
Unspecified
$5.3M
Series A (2018): $11M, investors not publicly disclosed
Unspecified (2021): $42M led by Tuobang Capital, Yonghua Capital, Juming Capital, Panlin Capital, Taifu Capital, and Biotrack Capital
Unspecified (2022): $5.3M, investors not publicly disclosed
Key Investors in NuProbe
Yonghua Capital
Shanghai Yonghua Investment Management Co Ltd is a private equity investment firm specializing in targeting and enhancing the value of Chinese enterprises.
Biotrack Capital
A venture capital firm focused on the healthcare and life sciences sector, providing strategic backing to innovative biotech and diagnostic companies.
Tuobang Capital
An investment firm that provides growth capital to emerging technology and healthcare enterprises, supporting long-term industrial development.
What's next for NuProbe?
With the recent capital infusion, NuProbe is expected to scale its operational capacity and deepen its research pipeline. The strategic focus will likely shift toward optimizing its molecular diagnostic platforms for broader adoption in research settings, while simultaneously navigating the regulatory pathways required for future clinical applications. As the company continues to refine its sequencing technologies, it remains a critical player in the evolution of precision medicine, with a clear mandate to deliver affordable and accurate disease state information to the global scientific community.
See full NuProbe company page
